Next Article in Journal
Tryptophanol-Derived Oxazolopyrrolidone Lactams as Potential Anticancer Agents against Gastric Adenocarcinoma
Next Article in Special Issue
cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
Previous Article in Journal
Levothyroxine Interactions with Food and Dietary Supplements–A Systematic Review
 
 
Review

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma

Department of Hematology, Centre Henri Becquerel, 76038 Rouen, France
*
Author to whom correspondence should be addressed.
Academic Editor: Alfredo Berzal-Herranz
Pharmaceuticals 2021, 14(3), 207; https://doi.org/10.3390/ph14030207
Received: 13 February 2021 / Revised: 25 February 2021 / Accepted: 26 February 2021 / Published: 2 March 2021
(This article belongs to the Special Issue Cell-Free DNA for the Management of Lymphoma)
Cell-free DNA (cfDNA) testing, is an emerging “liquid biopsy” tool for noninvasive lymphoma detection, and an increased amount of data are now available to use this technique with accuracy, especially in classical Hodgkin lymphoma (cHL). The advantages of cfDNA include simplicity of repeated blood sample acquisition over time; dynamic, noninvasive, and quantitative analysis; fast turnover time; reasonable cost; and established consistency with results from tumor genomic DNA. cfDNA analysis offers an easy method for genotyping the overall molecular landscape of pediatric and adult cHL and may help in cases of diagnostic difficulties between cHL and other lymphomas. cfDNA levels are correlated with clinical, prognostic, and metabolic features, and may serve as a therapeutic response evaluation tool and as a minimal residual disease (MRD) biomarker in complement to positron emission tomography (PET). Indeed, cfDNA real-time monitoring by fast high-throughput techniques enables the prompt detection of refractory disease or may help to address PET residual hypermetabolic situations during or at the end of treatment. The major recent works presented and described here demonstrated the clinically meaningful applicability of cfDNA testing in diagnostic and theranostic settings, but also in disease risk assessment, therapeutic molecular response, and monitoring of cHL treatments. View Full-Text
Keywords: cell-free DNA; Hodgkin lymphoma; precision medicine; liquid biopsy; circulating tumor DNA cell-free DNA; Hodgkin lymphoma; precision medicine; liquid biopsy; circulating tumor DNA
Show Figures

Figure 1

MDPI and ACS Style

Camus, V.; Jardin, F. Cell-Free DNA for the Management of Classical Hodgkin Lymphoma. Pharmaceuticals 2021, 14, 207. https://doi.org/10.3390/ph14030207

AMA Style

Camus V, Jardin F. Cell-Free DNA for the Management of Classical Hodgkin Lymphoma. Pharmaceuticals. 2021; 14(3):207. https://doi.org/10.3390/ph14030207

Chicago/Turabian Style

Camus, Vincent, and Fabrice Jardin. 2021. "Cell-Free DNA for the Management of Classical Hodgkin Lymphoma" Pharmaceuticals 14, no. 3: 207. https://doi.org/10.3390/ph14030207

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop